Clinical Trials Directory

Trials / Unknown

UnknownNCT01928654

Comparison Between Treatment With Yellow Micropulse Laser and Green Conventional Laser in Diabetic Macular Edema

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
32 (estimated)
Sponsor
Luigi Sacco University Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Macular edema is the most important cause of visual impairment in diabetic patients. Intravitreal injections of antiVEGF (vascular endothelial growth factor) agents and laser treatment are two effective therapies for stabilising visual acuity. However, antiVEGF therapy is very expensive and potentially needs to to be repeated for all patients life. Laser treatment, according to modified ETDRS (early treatment diabetic retinopathy study), produces retinal burns with possible negative consequences such as alterations in the visual fields. With micropulse treatment modality laser energy is delivered in short pulses ("micropulses") rather than as a continuous wave. In this way the amount of energy delivered to the retina and retinal pigment epithelium (RPE) is significantly reduced. This finer control of the photothermal effects should avoid any retinal and RPE damage. At the same time, according to several published reports, the efficacy of treatment appears to be equivalent to conventional laser therapy. Previous studies investigated the effects of 810nm micropulse laser therapy. Recently, this treatment modality has been made available also with 577nm wavelength, which corresponds to the maximum absorption level for blood. Aim of this study is to assess the safety and efficacy of 577nm micropulse laser treatment compared to conventional modified ETDRS laser therapy.

Conditions

Interventions

TypeNameDescription
DEVICEMicropulse laser treatmentDevice for subthreshold treatment of the retina, by decomposing a continuos wave of laser in micropulses, with 5% duty cycle, 200 milliseconds, 100 microns, and power adjusted according to patient's diopter transparency and pigmentation.
DEVICELaser modified ETDRSDevice for visible treatment of the retina, with direct treatment of microaneurysms or grid pattern covering the area of retinal edema.

Timeline

Start date
2013-07-01
Primary completion
2014-10-01
Completion
2014-11-01
First posted
2013-08-27
Last updated
2014-03-19

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT01928654. Inclusion in this directory is not an endorsement.